Priority Review awarded to Xtandi for prostate cancer

22nd August 2019 Uncategorised 0

Back in February, the companies revealed results from the Phase III ARCHES trial in men with mHSPC.

More: Priority Review awarded to Xtandi for prostate cancer
Source: News